Explain this page
Arphra AIPlain-English read on Abbott Laboratories’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$140.62
+59.11% vs spot
Recommendation
Strong Buy
18 of 19 methods
Method spread
7bull10bear
±5% threshold
Analyst PT consensus: $127.46 (+44.22%)
Candlestick · 1Y
Open in chart workstation →ABT
88.41-33.52%H 139.06L 81.97MA50 90.13MA200 113.64Avg vol 9.0M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.14% | +0.14% | 0.00% | -16.20% | -29.55% | -29.46% | -33.54% | -17.17% | -20.69% | +134.12% | +53577.50% |
Insider · 30d
History →Bought
$2.22M
4 txns
Sold
$485.32K
6 txns
Net flow
+$1.73M
Aftermarket
LiveLast trade
$88.74
Bid
$88.40
100 sh
Ask
$89.00
100 sh
Spread
$0.600
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $11.16B | $1.08B | $0.62 |
| Q4 Dec 2025 | $11.46B | $1.78B | $1.02 |
| Q3 Sep 2025 | $11.37B | $1.64B | $0.94 |
| Q2 Jun 2025 | $11.14B | $1.78B | $1.01 |
| Q1 Mar 2025 | $10.36B | $1.33B | $0.76 |
| Q4 Dec 2024 | $10.97B | $9.23B | $5.27 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$127.46
+44.22% upside
Low
$92.00
Median
$125.00
High
$152.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Should You Buy Abbott Labs Stock Hand Over Fist Before July 16?fool.com·Jun 20, 2026
- Living Longer Is Big Business. These Stocks Will Benefit.barrons.com·Jun 18, 2026
- The Healthcare M&A Waveforbes.com·Jun 17, 2026
- Abbott's CGM Growth Story Stays Intact Despite Q1 Moderationzacks.com·Jun 16, 2026
- The Hormuz Reopening Trade: These 20 Large-Cap Stocks Still Haven't Caught Up To Pre-War Levelsbenzinga.com·Jun 15, 2026
- Abbott (ABT) Stock Declines While Market Improves: Some Information for Investorszacks.com·Jun 12, 2026
- Abbott declares 410th consecutive quarterly dividendgurufocus.com·Jun 12, 2026
- Abbott declares 410th consecutive quarterly dividendprnewswire.com·Jun 12, 2026
Recent analyst activity
DB- Jun 17, 2026GradeBuy → BuyCiti sum-of-the-parts analysis shows Abbott share upsideCitigroup
Financial scores
DBJun 19, 2026Altman Z
3.01
Safe
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
6/9
Average
≥ 7 strong · 4–6 average · < 4 weak
Peers
- UNHUnitedHealth Group Incorporated$368.78$334.73B
- NVSNovartis AG$146.57$279.67B
- MRKMerck & Co., Inc.$112.17$277.03B
- NVONovo Nordisk A/S$43.88$195B
- TMOThermo Fisher Scientific Inc.$469.21$174.37B
- GILDGilead Sciences, Inc.$131.65$163.41B
- ISRGIntuitive Surgical, Inc.$457.78$162.13B
- SYKStryker Corporation$294.73$112.88B
Total assets
$86.71B
Total debt
$15.07B
Cash & equiv
$8.52B
Operating CF
$9.57B
Free cash flow
$7.4B
Buybacks
-$893M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
STARKS DANIEL J director | Buy | 10,000 | $926.54K | Apr 27, 2026 |
Boudreau Philip P officer: EVP AND CFO | Buy | 2,200 | $201.3K | Apr 23, 2026 |
MCCOY JOHN A. JR. officer: VICE PRESIDENT AND CONTROLLER | Sell | 585 | $67.61K | Mar 02, 2026 |
Shroff Eric officer: Senior Vice President | Sell | 709 | $81.95K | Mar 02, 2026 |
Cushman Elizabeth C. officer: EVP, GC AND SECRETARY | Sell | 263 | $30.4K | Mar 02, 2026 |
Salvadori Daniel Gesua Sive officer: EVP AND GROUP PRESIDENT | Sell | 885 | $102.29K | Mar 02, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $44.33B | $8.05B | $6.52B | $3.72 | +14.72% |
| FY 2024 | $41.95B | $6.83B | $13.4B | $7.64 | +31.95% |
| FY 2023 | $40.11B | $6.44B | $5.72B | $3.27 | +14.27% |
| FY 2022 | $43.65B | $8.36B | $6.93B | $3.91 | +15.88% |
| FY 2021 | $43.08B | $9.2B | $7.07B | $3.94 | +16.42% |